Abstract
Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by a preferential degeneration of dopaminergic neurons in the substantia nigra pars compacta. This results in a profound decrease of striatal dopamine (DA) levels, which in turn leads to the cardinal motor symptoms of PD; muscle rigidity, hypo- and bradykinesia and resting tremor. Even 50 years after its initial use, the DA precursor levodopa (L-dopa), is still the most effective medical therapy for the symptomatic treatment of PD. Long-term L-dopa treatment is however, unfortunately associated with undesirable side effects such as motor fluctuations and dyskinesias. Furthermore, despite the disease alleviating effects of L-dopa, it is still discussed whether L-dopa has a neurotoxic or neuroprotective effect on dopaminergic neurons. Here we review the history of L-dopa, including its discovery, development and current use in the treatment of PD. We furthermore review current evidence of the L-dopa-induced side effects and perspectives of L-dopa treatment in PD compared to other established treatments such as DA-agonists and the inhibitors of catechol-o-methyltransferase and monoamine oxidase B.
Keywords: Dopamine, dopaminergic, substantia nigra, L-dopa, dyskinesia, Parkinson’s Disease (PD).
CNS & Neurological Disorders - Drug Targets
Title:Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives
Volume: 19 Issue: 8
Author(s): Helle Bogetofte, Arezo Alamyar, Morten Blaabjerg and Morten Meyer*
Affiliation:
- Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense,Denmark
Keywords: Dopamine, dopaminergic, substantia nigra, L-dopa, dyskinesia, Parkinson’s Disease (PD).
Abstract: Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by a preferential degeneration of dopaminergic neurons in the substantia nigra pars compacta. This results in a profound decrease of striatal dopamine (DA) levels, which in turn leads to the cardinal motor symptoms of PD; muscle rigidity, hypo- and bradykinesia and resting tremor. Even 50 years after its initial use, the DA precursor levodopa (L-dopa), is still the most effective medical therapy for the symptomatic treatment of PD. Long-term L-dopa treatment is however, unfortunately associated with undesirable side effects such as motor fluctuations and dyskinesias. Furthermore, despite the disease alleviating effects of L-dopa, it is still discussed whether L-dopa has a neurotoxic or neuroprotective effect on dopaminergic neurons. Here we review the history of L-dopa, including its discovery, development and current use in the treatment of PD. We furthermore review current evidence of the L-dopa-induced side effects and perspectives of L-dopa treatment in PD compared to other established treatments such as DA-agonists and the inhibitors of catechol-o-methyltransferase and monoamine oxidase B.
Export Options
About this article
Cite this article as:
Bogetofte Helle , Alamyar Arezo , Blaabjerg Morten and Meyer Morten *, Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives, CNS & Neurological Disorders - Drug Targets 2020; 19 (8) . https://dx.doi.org/10.2174/1871527319666200722153156
DOI https://dx.doi.org/10.2174/1871527319666200722153156 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peak Treadmill Exercise Echocardiography
Reviews on Recent Clinical Trials Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology TakoTsubo Cardiomyopathy A Short Review
Current Cardiology Reviews GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets New Trends in the Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I
Current Neuropharmacology 5-HT2 Receptors
Current Drug Targets - CNS & Neurological Disorders Anti-Inflammatory Agents in Parkinsons Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Drug-Induced Impulse Control Disorders: A Review
Current Clinical Pharmacology Sleep in Interstitial Lung Disease
Current Respiratory Medicine Reviews Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics
Current Molecular Medicine Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
Current Neuropharmacology Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets